rafoxanide has been researched along with Lymphoma, Large B-Cell, Diffuse in 1 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 1 (100.00) | 2.80 |
| Authors | Studies |
|---|---|
| Chen, G; Feng, Q; Gao, L; He, W; Hu, L; Li, B; Shi, J; Song, D; Tao, Y; Wu, X; Xu, Z; Yu, D; Zhang, H; Zhang, Y; Zhu, W | 1 |
1 other study(ies) available for rafoxanide and Lymphoma, Large B-Cell, Diffuse
| Article | Year |
|---|---|
Antitumor effects of rafoxanide in diffuse large B cell lymphoma via the PTEN/PI3K/Akt and JNK/c-Jun pathways.
Topics: Animals; Antineoplastic Agents; Cell Cycle Checkpoints; DNA Damage; Humans; Lymphoma, Large B-Cell, Diffuse; Male; MAP Kinase Kinase 4; Mice; Phosphatidylinositol 3-Kinases; Proto-Oncogene Proteins c-akt; Proto-Oncogene Proteins c-jun; PTEN Phosphohydrolase; Rafoxanide; Reactive Oxygen Species; Xenograft Model Antitumor Assays | 2020 |